Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells

Biochemical Pharmacology

Volumn 72, Issue 1, 2006, Pages 19-31

  Merighi, Stefania ^a   Benini, Annalisa ^a   Mirandola, Prisco ^b   Gessi, Stefania ^a   Varani, Katia ^a   Leung, Edward ^c   Maclennan, Stephen ^c   Borea, Pier Andrea ^a,d  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c King Pharmaceuticals   (United States)

^d Interdisciplinary Center for the Study of Inflammation   (Italy)

Author keywords

A3 receptors; Adenosine; Glioblastoma; HIF 1 ; Hypoxia; VEGF

Indexed keywords

2 (2 FURYL) 5 [3 (4 METHOXYPHENYL)UREIDO] 8 PROPYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38; MRE 3005F20; PROTEIN P42; PROTEIN P44; PYRIMIDINE DERIVATIVE; RECEPTOR SUBTYPE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYPOXIC CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR INTRINSIC ACTIVITY; UPREGULATION;

ADENOSINE; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENYLUREA COMPOUNDS; RECEPTOR, ADENOSINE A3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRIAZOLES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646909636     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.03.020     Document Type: Article

References (48)

1. Lacroix M., Abi-Said D., Fourney D.R., Gokaslan Z.L., Shi W., DeMonte F., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95 (2001) 190-198
2. Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61 (2002) 215-229
3. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 (2004) 437-447
4. Melillo G. HIF-1: a target for cancer, ischemia and inflammation-too good to be true?. Cell Cycle 3 (2004) 154-155
5. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88 (2000) 1474-1480
6. Giaccia A., Siim B.G., and Johnson R.S. HIF-1 as a target for drug development. Nat Rev Drug Discov 2 (2003) 803-811
7. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
8. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., et al. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 59 (1999) 5830-5835
9. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., et al. HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
10. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94 (1997) 8104-8109
11. Kung A.L., Wang S., Klco J.M., Kaelin W.G., and Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6 (2000) 1335-1340
12. Ratcliffe P.J., Pugh C.W., and Maxwell P.H. Targeting tumors through the HIF system. Nat Med 6 (2000) 1315-1316
13. Kaur B., Khwaja F.W., Severson E.A., Matheny S.L., Brat D.J., and Van Meir E.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncol 7 (2005) 134-153
14. Ralevic V., and Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 50 (1998) 413-492
15. Blay J., White T.D., and Hoskin D.W. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57 (1997) 2602-2605
16. Merighi S., Mirandola P., Varani K., Gessi S., Leung E., Baraldi P.G., et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100 (2003) 31-48
17. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.N., and Linden J. International Union of Pharmacology. Part XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53 (2001) 527-552
18. Merighi S., Mirandola P., Milani D., Varani K., Gessi S., Klotz K.N., et al. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 119 (2002) 923-933
19. Merighi S., Baraldi P.G., Gessi S., Iannotta V., Klotz K.N., Leung E., et al. Adenosine receptors and human melanoma. Drug Dev Res 58 (2003) 377-385
20. 3 mast cells from apoptosis. Mol Pharmacol 59 (2001) 76-82
21. 3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem 278 (2003) 42121-42130
22. 3 adenosine receptors in Jurkat T cells. Br J Pharmacol 134 (2001) 116-126
23. Merighi S., Varani K., Gessi S., Cattabriga E., Iannotta V., Ulouglu C., et al. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br J Pharmacol 134 (2001) 1215-1226
24. Suh B.C., Kim T.D., Lee J.U., Seong J.K., and Kim K.T. Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells. Br J Pharmacol 134 (2001) 132-142
25. 3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol Pharmacol 61 (2002) 415-424
26. 3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 10 (2004) 5895-5901
27. 3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 10 (2004) 4472-4479
28. 2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am J Pathol 164 (2004) 1887-1892
29. 2B angiogenic phenotype. Hypertension 44 (2004) 649-654
30. 3 adenosine receptors. Circ Res 92 (2003) 485-492
31. 2B receptors in angiogenic factor regulation. Circ Res 90 (2002) 531-538
32. 2A receptor agonists and endotoxin. Am J Pathol 160 (2002) 2231-2244
33. 3 adenosine receptors modulate hypoxia-inducible factor 1α expression in human A375 melanoma cells. Neoplasia 7 (2005) 894-903
34. Synnestvedt K., Furuta G.T., Comerford K.M., Louis N., Karhausen J., Eltzschig H.K., et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110 (2002) 993-1002
35. Sitkovsky M., and Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF-1 alpha and adenosine receptors. Nat Rev Immunol. 5 (2005) 712-721
36. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
37. 3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 280 (2005) 19516-19526
38. Warnecke C., Zaborowska Z., Kurreck J., Erdmann V.A., Frei U., Wiesener M., et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1 alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 18 (2004) 1462-1464
39. Klotz K.N. Adenosine receptors and their ligands. N-S Arch Pharmacol 362 (2000) 382-391
40. Merighi S., Mirandola P., Varani K., Gessi S., Capitani S., Leung E., et al. Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine. Biochem Pharmacol 66 (2003) 739-748
41. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev 2 (2002) 38-47
42. Kung A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004) 33-43
43. Sun X., Kanwar J.R., Leung E., Lehnert K., Wang D., and Krissansen G.W. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 8 (2001) 638-645
44. Dachs G.U., Coralli C., Hart S.L., and Tozer G.M. Gene delivery to hypoxic cells in vitro. Br J Cancer 83 (2000) 662-667
45. Rapisarda A., Zalek J., Hollingshead M., Braunschweig T., Uranchimeg B., Bonomi C.A., et al. Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64 (2004) 6845-6848
46. Chau N.M., Rogers P., Aherne W., Carroll V., Collins I., McDonald E., et al. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1 alpha induction in response to hypoxic stress and growth factors. Cancer Res 65 (2005) 4918-4928
47. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
48. Isaacs J.S., Jung Y.J., and Neckers L. Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1 alpha by modulating an Hsp90-dependent regulatory pathway. J Biol Chem 279 (2004) 16128-16135